Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colm Keane

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Blood Advances|April 9, 2020
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaColm Keane, Soi C Law, Clare Gould, et al.
Blood|April 19, 2015
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingDavid M Kurtz, Michael R Green, Scott V Bratman, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Leukemia & Lymphoma|March 24, 2023
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortPrashasti Agrawal, Kevin A David, Zhengming Chen, et al.
Cancer Discovery|March 24, 2026
Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor MicroenvironmentStephanie Pei Tung Yiu, Yuzhou Chang, Yao Yu Yeo, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Blood Advances|April 9, 2020
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaColm Keane, Soi C Law, Clare Gould, et al.
Blood|April 19, 2015
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingDavid M Kurtz, Michael R Green, Scott V Bratman, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Leukemia & Lymphoma|March 24, 2023
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortPrashasti Agrawal, Kevin A David, Zhengming Chen, et al.
Cancer Discovery|March 24, 2026
Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor MicroenvironmentStephanie Pei Tung Yiu, Yuzhou Chang, Yao Yu Yeo, et al.
Pageof 7